Published in J Viral Hepat on February 01, 2006
Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut (2006) 1.34
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol (2014) 1.06
Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. Am J Obstet Gynecol (2008) 1.00
Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol (2014) 0.98
Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med (2014) 0.94
Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol (2009) 0.92
Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol (2016) 0.91
Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol (2009) 0.87
2D MR Spectroscopy Combined with Prior-Knowledge Fitting Is Sensitive to HCV-Associated Cerebral Metabolic Abnormalities. Int J Hepatol (2012) 0.86
Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterol Hepatol (N Y) (2012) 0.84
Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response. PLoS One (2017) 0.83
Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin. Lab Invest (2014) 0.83
Central portalization correlates with fibrosis but not with risk factors for nonalcoholic steatohepatitis in steatotic chronic hepatitis C. Int J Hepatol (2014) 0.81
Nonstructural 5A protein of hepatitis C virus interacts with pyruvate carboxylase and modulates viral propagation. PLoS One (2013) 0.80
Steatosis and hepatitis C. Gastroenterol Rep (Oxf) (2015) 0.79
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol (2016) 0.77
Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C. Biomed Res Int (2014) 0.77
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The "Musketeer" in the Spotlight. Int J Mol Sci (2016) 0.76
An insight into the molecular characteristics of hepatitis C virus for clinicians. Saudi Med J (2016) 0.76
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. World J Hepatol (2014) 0.76
Chronic hepatitis B associated with hepatic steatosis, insulin resistance, necroinflammation and fibrosis. Afr Health Sci (2015) 0.75
The impact of host metabolic factors on treatment outcome in chronic hepatitis C. Gastroenterol Res Pract (2012) 0.75
PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally. Antimicrob Agents Chemother (2016) 0.75
HIV-infected and Uninfected Adults with Non-Genotype 3 Hepatitis C Virus Have Less Hepatic Steatosis than Adults with Neither Infection. Hepatology (2016) 0.75
Recurrence of Disease Following Liver Transplantation: Nonalcoholic Steatohepatitis vs Hepatitis C Virus Infection. Int J Organ Transplant Med (2011) 0.75
Hepatitis virus C infection, adipokines and hepatic steato-fibrosis. J Med Life (2010) 0.75
Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol (2017) 0.75
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology (2001) 3.80
Comparison of enhanced Mycobacterium tuberculosis amplified direct test with COBAS AMPLICOR Mycobacterium tuberculosis assay for direct detection of Mycobacterium tuberculosis complex in respiratory and extrapulmonary specimens. J Clin Microbiol (2000) 2.54
Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (M.I.COL.) Am J Epidemiol (1995) 2.09
Streptococcus bovis endocarditis and its association with chronic liver disease: an underestimated risk factor. Clin Infect Dis (2004) 1.80
Ambulatory 24-hr pH monitoring of esophagus, fundus, and antrum. A new technique for simultaneous study of gastroesophageal and duodenogastric reflux. Dig Dis Sci (1990) 1.76
Recognition of autologous dendritic cells by human NK cells. Eur J Immunol (1999) 1.63
A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Exp Med (1997) 1.59
Influence of age and sex on serum concentrations of total dimeric activin A. Eur J Endocrinol (1998) 1.54
Direct identification of mycobacteria from MB/BacT alert 3D bottles: comparative evaluation of two commercial probe assays. J Clin Microbiol (2001) 1.46
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis (2010) 1.45
Inhibition of heme detoxification processes underlies the antimalarial activity of terpene isonitrile compounds from marine sponges. J Med Chem (2001) 1.41
Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia. Eur J Gastroenterol Hepatol (1997) 1.40
Comparison of MB/Bact alert 3D system with radiometric BACTEC system and Löwenstein-Jensen medium for recovery and identification of mycobacteria from clinical specimens: a multicenter study. J Clin Microbiol (2001) 1.40
Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology (1997) 1.36
Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo. Infect Immun (1988) 1.36
Bile lipid composition and bile acid pool size in diabetes. Am J Dig Dis (1978) 1.30
Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol (2001) 1.23
Glutathione, ascorbic acid and antioxidant enzymes in the tumor tissue and blood of patients with oral squamous cell carcinoma. Eur Rev Med Pharmacol Sci (2006) 1.15
Luminosity-independent measurement of the proton-proton total cross section at √s=8 TeV. Phys Rev Lett (2013) 1.13
Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci (2001) 1.11
Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease. Am J Gastroenterol (2001) 1.10
Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis (2007) 1.07
Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis (2002) 1.06
Alcohol-drugs interaction in man: alcohol and tolbutamide. Eur J Clin Invest (1971) 1.05
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther (2006) 1.01
Differences in the rate of ethanol metabolism in recently drinking alcoholic and nondrinking subjects. Am J Clin Nutr (1969) 0.99
Review article: diabetes, genetics and ethnicity. Aliment Pharmacol Ther (2005) 0.98
Effects of acute changes of bile acid pool composition on biliary lipid secretion. J Clin Invest (1984) 0.97
Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study. Ital J Gastroenterol (1996) 0.97
Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther (2005) 0.96
Uptake of adenosylmethionine and related sulfur compounds by isolated rat liver. FEBS Lett (1978) 0.96
Protection of rabbits in an infection model of toxic shock syndrome (TSS) by a TSS toxin-1-specific monoclonal antibody. Infect Immun (1988) 0.96
Endotoxemia in a series of 104 patients with chronic liver diseases: prevalence and significance. Digestion (1982) 0.96
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat (2013) 0.95
Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies. Clin Transplant (2001) 0.94
'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol (2004) 0.94
Enhanced phagocytosis and bactericidal activity of hepatic reticuloendothelial system during endotoxin tolerance. Infect Immun (1980) 0.93
Hypervascular retroperitoneal mass in a patient with Fever and leucocytosis - contrast-enhanced ultrasonographic findings in a case of inflammatory malignant fibrous histiocytoma. Ultraschall Med (2010) 0.92
Review article: the metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2005) 0.92
Effect of the selective expansion of cholic acid pool on bile lipid composition: possible mechanism of bile acid induced biliary cholesterol desaturation. Gastroenterology (1981) 0.92
Measurement of plasma volu using 99Tcm, and 113Inm labelled proteins. Br J Radiol (1969) 0.92
Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short erm feeding of chenodeoxycholic and ursodeoxycholic acid. J Lipid Res (1980) 0.92
Bile acid feeding and hepatic sterol metabolism: effect of deoxycholic acid. Gastroenterology (1980) 0.91
Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat (2008) 0.91
Increased phagocytosis and killing of Escherichia coli treated with subinhibitory concentrations of cefamandole and gentamicin in isolated rat livers. Antimicrob Agents Chemother (1984) 0.91
Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis. Infect Immun (1985) 0.91
Effect of small doses of deoxycholic acid on bile cholesterol saturation in patients with liver cirrhosis. Gut (1986) 0.91
Dual or single hepatitis B and C virus infections in childhood cancer survivors: long-term follow-up and effect of interferon treatment. Blood (1999) 0.91
Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial. J Clin Pharmacol (1981) 0.89
Intestinal solubilization, absorption, pharmacokinetics and bioavailability of chenodeoxycholic acid. Eur J Clin Invest (1980) 0.89
Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis (2009) 0.89
A novel extracellular subtilisin-like protease from the hyperthermophile Aeropyrum pernix K1: biochemical properties, cloning, and expression. Extremophiles (2003) 0.89
Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol (1996) 0.88
Cholesterol absorption during bile acid feeding. Effect of ursodeoxycholic acid (UDCA) administration. Gastroenterology (1980) 0.88
Decreased phagocytic and bactericidal activity of the hepatic reticuloendothelial system during chronic ethanol treatment and its restoration by levamisole. J Reticuloendothel Soc (1982) 0.88
Review article: hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther (2005) 0.88
Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients. Eur J Gastroenterol Hepatol (2000) 0.88
Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des (2002) 0.87
ER stress impairs MHC Class I surface expression and increases susceptibility of thyroid cells to NK-mediated cytotoxicity. Biochim Biophys Acta (2011) 0.87
Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment. J Viral Hepat (2002) 0.87
Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci. Eur J Clin Microbiol Infect Dis (1998) 0.86
Age-related changes in bile acid synthesis and hepatic nuclear receptor expression. Eur J Clin Invest (2007) 0.86
Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: insights from evidence on hepatic cholesterol degradation and gallstone disease in humans. Curr Med Chem (2008) 0.85
Influence of small-bowel transit time on dietary cholesterol absorption in human beings. N Engl J Med (1982) 0.85
Alteration of drug metabolism in Gilbert's syndrome. Gut (1976) 0.85
A novel thermoacidophilic cellulase from Alicyclobacillus acidocaldarius. Protein Pept Lett (2008) 0.85
The effect of chenodeoxycholic acid (CDCA) on cholesterol absorption. Gastroenterology (1979) 0.85
Gallstone dissolution after 6 months of ursodeoxycholic acid (UDCA): effectiveness of different doses. J Int Med Res (1982) 0.84
Effect of aging on cholesterol 7 alpha-hydroxylation in humans. J Lipid Res (1993) 0.84
Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR. J Viral Hepat (2011) 0.83
Presence of endotoxemia and its relationship to liver dysfunction in patients with typhoid fever. Infection (1987) 0.83
Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7 alpha-hydroxylation rates in vivo. Hepatology (1991) 0.83
Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. Hepatology (1999) 0.83
Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection. Intervirology (2003) 0.83
[Bile composition in patients with high risk of cholelithiasis]. Minerva Med (1976) 0.82
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis (2013) 0.82
Secondary immune-mediated thrombocytopenia in dogs naturally infected by Leishmania infantum. Vet Rec (2009) 0.82
Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis. Eur J Clin Invest (2006) 0.82